BACKGROUND: Hepatopulmonary syndrome is a pulmonary vascular complication of cirrhosis in which intrapulmonary vasodilatation (IPV) results in hypoxemia. Endothelin-1 (ET-1), produced by proliferating cholangiocytes, has been identified as a mediator of IPV in an animal model of HPS, but the pathophysiology of IPV in humans has not been defined. AIM: The purpose of this study was to assess whether cirrhosis with IPV, which often leads to HPS, is associated with increased hepatic venous ET-1 blood levels. METHODS: We performed a prospective cohort pilot study of 40 patients with liver disease undergoing transjugular liver biopsy from November 1, 2008 to September 1, 2009. Patients were categorized according to absence (-) or presence (+) of IPV as determined by bubble-contrasted echocardiography. Hepatic venous blood was assayed for ET-1 by ELISA. The percent volume of cholangiocytes in the liver biopsy specimen was determined by morphometric analysis, as a measure of bile duct proliferation. RESULTS: Nine subjects were excluded, due to absence of cirrhosis (6) and patent foramen ovale (3). Of the remaining 31 subjects, IPV was present in 18 (58%). Median hepatic venous ET-1 was higher with IPV+ than IPV- at levels of 9.1 pg/mL (range 7.5-11.7) versus 2.1 pg/mL (1.3-5.6), respectively (P = 0.004). ET-1 levels correlated positively with cholangiocyte percent volume (r = 0.72, P < 0.001) but not with measures of liver dysfunction (bilirubin, INR, MELD score, or hepatic venous pressure gradient). CONCLUSION: In human cirrhosis, increased hepatic venous ET-1 is associated with IPV and increased hepatic cholangiocyte volume.
BACKGROUND:Hepatopulmonary syndrome is a pulmonary vascular complication of cirrhosis in which intrapulmonary vasodilatation (IPV) results in hypoxemia. Endothelin-1 (ET-1), produced by proliferating cholangiocytes, has been identified as a mediator of IPV in an animal model of HPS, but the pathophysiology of IPV in humans has not been defined. AIM: The purpose of this study was to assess whether cirrhosis with IPV, which often leads to HPS, is associated with increased hepatic venousET-1 blood levels. METHODS: We performed a prospective cohort pilot study of 40 patients with liver disease undergoing transjugular liver biopsy from November 1, 2008 to September 1, 2009. Patients were categorized according to absence (-) or presence (+) of IPV as determined by bubble-contrasted echocardiography. Hepatic venous blood was assayed for ET-1 by ELISA. The percent volume of cholangiocytes in the liver biopsy specimen was determined by morphometric analysis, as a measure of bile duct proliferation. RESULTS: Nine subjects were excluded, due to absence of cirrhosis (6) and patent foramen ovale (3). Of the remaining 31 subjects, IPV was present in 18 (58%). Median hepatic venousET-1 was higher with IPV+ than IPV- at levels of 9.1 pg/mL (range 7.5-11.7) versus 2.1 pg/mL (1.3-5.6), respectively (P = 0.004). ET-1 levels correlated positively with cholangiocyte percent volume (r = 0.72, P < 0.001) but not with measures of liver dysfunction (bilirubin, INR, MELD score, or hepatic venous pressure gradient). CONCLUSION: In humancirrhosis, increased hepatic venousET-1 is associated with IPV and increased hepatic cholangiocyte volume.
Authors: Junlan Zhang; Yiqun Ling; Liping Tang; Bao Luo; Balu K Chacko; Rakesh P Patel; Michael B Fallon Journal: J Appl Physiol (1985) Date: 2006-11-16
Authors: Bao Luo; Liping Tang; Zhishan Wang; Junlan Zhang; Yiqun Ling; Wenguang Feng; Ju-Zhong Sun; Cecil R Stockard; Andra R Frost; Yiu-Fai Chen; William E Grizzle; Michael B Fallon Journal: Gastroenterology Date: 2005-08 Impact factor: 22.682
Authors: Sandra Leal; Carmen Diniz; Carlos Sá; Jorge Gonçalves; Ana Sofia Soares; Carolina Rocha-Pereira; Paula Fresco Journal: Anal Biochem Date: 2006-08-01 Impact factor: 3.365
Authors: P S Kamath; H A Carpenter; R V Lloyd; M A McKusick; J L Steers; D M Nagorney; V M Miller Journal: Liver Transpl Date: 2000-09 Impact factor: 5.799
Authors: Bao Luo; Lichuan Liu; Liping Tang; Junlan Zhang; Cecil R Stockard; William E Grizzle; Michael B Fallon Journal: J Hepatol Date: 2003-05 Impact factor: 25.083
Authors: Michael J Krowka; M Susan Mandell; Michael A E Ramsay; Steve M Kawut; Michael B Fallon; Cosme Manzarbeitia; Manuel Pardo; Paul Marotta; Shinji Uemoto; Markus P Stoffel; Joanne T Benson Journal: Liver Transpl Date: 2004-02 Impact factor: 5.799
Authors: Kumiko Isse; Andrew Lesniak; Kedar Grama; John Maier; Susan Specht; Marcela Castillo-Rama; John Lunz; Badrinath Roysam; George Michalopoulos; Anthony J Demetris Journal: Hepatology Date: 2013-03-19 Impact factor: 17.425